title: Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel.
abstract: OBJECTIVE
  The present study discusses paclitaxel (PTX)-loaded mannosylated-DSPE (Distearoyl-phosphatidyl-ethanolamine) solid lipid nanoparticles (M-SLNs) using mannose as a lectin receptor ligand conjugate for lung cancer targeting and to increase the anticancer activity of PTX against A549 lung's epithelial cancer cells.
  
  
  METHODS
  The PTX-SLNs were prepared by solvent injection method and mannose was conjugated to the free amine group of stearylamine. The M-SLNs obtained were characterized for their particle size, polydispersity index, zeta potential and morphology by transmission electron microscope.
  
  
  RESULTS
  The M-SLNs were spherical in shape with 254 ± 2.3 nm average size, positive zeta potential (3.27 mV), 79.4 ± 1.6 drug entrapment efficiency and showed the lower extent of drug release 40% over 48 h in vitro. Cytotoxicity study on A549 cell lines and biodistrubtion study of drug revealed that M-SLNs deliver a higher concentration of PTX as compared to PTX-SLNs in an alveolar cell site.
  
  
  CONCLUSIONS
  These results suggested that mannosylated M-SLNs are safe and potential vector for lung cancer targeting.
authors.affiliation: Pharmaceutics Division, Adina Institute of Pharmaceutical Sciences , Sagar, Madhya Pradesh , India.
authors.forename: Piyush Kumar
authors.initials: PK
authors.lastname: Sahu
authors.forename: Deepak Kumar
authors.initials: DK
authors.lastname: Mishra
authors.forename: Nivrati
authors.initials: N
authors.lastname: Jain
authors.forename: Vaibhav
authors.initials: V
authors.lastname: Rajoriya
authors.forename: Ashish Kumar
authors.initials: AK
authors.lastname: Jain
mesh_terms: D065567:Absorption, Physiological; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001682:Biological Availability; D045744:Cell Line, Tumor; D004339:Drug Compounding; D016503:Drug Delivery Systems / Q000009:adverse effects; D065546:Drug Liberation; D004355:Drug Stability; D004356:Drug Storage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008358:Mannose / Q000031:analogs & derivatives* / Q000737:chemistry; D053758:Nanoparticles / Q000009:adverse effects / Q000737:chemistry* / Q000648:ultrastructure; D017239:Paclitaxel / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D010316:Particle Size; D010714:Phosphatidylethanolamines / Q000009:adverse effects / Q000737:chemistry*; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D051381:Rats; D013499:Surface Properties; D014018:Tissue Distribution; D014280:Triglycerides / Q000009:adverse effects / Q000737:chemistry; D023041:Xenograft Model Antitumor Assays
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D010714:Phosphatidylethanolamines; D014280:Triglycerides; C038089:1,2-distearoylphosphatidylethanolamine; C022618:tristearin; D017239:Paclitaxel; D008358:Mannose
keywords: Lung cancer targeting; SRB assay; mannosylation; paclitaxel; solid lipid nanoparticles